Alfredo Garzino-Demo

Dr. Alfredo Garzino-Demo

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in Journal of Virology
Verified
Journal Article
Closed access
PDF file
ACAaron Christensen-Quick
Aaron Christensen-Quick
MLMark Lafferty
Mark Lafferty
LSLingling Sun
Lingling Sun
LMLuigi Marchionni
Luigi Marchionni
ADAnthony DeVico
Anthony DeVico
AGAlfredo Garzino-Demo
Alfredo Garzino-Demo
Human immunodeficiency virus (HIV) infects and depletes CD4 + T cells, but subsets of CD4 + T cells vary in their susceptibility and permissiveness to infection. For example, HIV preferentially depletes interleukin-17 (IL-17)-producing T helper 17 (T h 17) cells and T follicular helper (T fh ) cells. The preferential loss of T h 17 cells during the acute phase of infection impairs the integrity of the gut mucosal barrier, which drives chronic immune activation—a key determinant of disease progression. The preferential loss of T h 17 cells has been attributed to high CD4, CCR5, and CXCR4 expression. Here, we show that T h 17 cells also exhibit heightened permissiveness to productive HIV infection. Primary human CD4 + T cells were sorted, activated under T h 17- or T h 0-polarizing conditions and infected, and then analyzed by flow cytometry. T h 17-polarizing cytokines increased HIV infection, and HIV infection was disproportionately higher among T h 17 cells than among IL-17 − or gamma interferon-positive (IFN-γ + ) cells, even upon infection with a replication-defective HIV vector with a pseudotype envelope. Further, T h 17-polarized cells produced more viral capsid protein. Our data also reveal that T h 17-polarized cells have diminished expression of RNase A superfamily proteins, and we report for the first time that RNase 6 inhibits HIV. Thus, our findings link T h 17 polarization to increased HIV replication. IMPORTANCE Our study compares the intracellular replicative capacities of several different HIV isolates among different T cell subsets, providing a link between the differentiation of T h 17 cells and HIV replication. T h 17 cells are of key importance in mucosal integrity and in the immune response to certain pathogens. Based on our findings and the work of others, we propose a model in which HIV replication is favored by the intracellular environment of two CD4 + T cell subsets that share several requirements for their differentiation: T h 17 and T fh cells. Characterizing cells that support high levels of viral replication (rather than becoming latently infected or undergoing cell death) informs the search for new therapeutics aimed at manipulating intracellular signaling pathways and/or transcriptional factors that affect HIV replication.

1 April 2016 in International Journal of Antimicrobial Agents
Verified
Journal Article
Open access
RPRosalba Perrone
Rosalba Perrone
EBElena Butovskaya
Elena Butovskaya
SLSara Lago
Sara Lago
AGAlfredo Garzino-Demo
Alfredo Garzino-Demo
CPChristophe Pannecouque
Christophe Pannecouque
SRSara Richter
Sara Richter
AS1411 is a G-rich aptamer that forms a stable G-quadruplex structure and displays antineoplastic properties both in vitro and in vivo. This oligonucleotide has undergone phase 2 clinical trials. The major molecular target of AS1411 is nucleolin (NCL), a multifunctional nucleolar protein also present in the cell membrane where it selectively mediates the binding and uptake of AS1411. Cell-surface NCL has been recognised as a low-affinity co-receptor for human immunodeficiency virus type 1 (HIV-1) anchorage on target cells. Here we assessed the anti-HIV-1 properties and underlying mechanism of action of AS1411. The antiviral activity of AS1411 was determined towards different HIV-1 strains, host cells and at various times post-infection. Acutely, persistently and latently infected cells were tested, including HIV-1-infected peripheral blood mononuclear cells from a healthy donor. Mechanistic studies to exclude modes of action other than virus binding via NCL were performed. AS1411 efficiently inhibited HIV-1 attachment/entry into the host cell. The aptamer displayed antiviral activity in the absence of cytotoxicity at the tested doses, therefore displaying a wide therapeutic window and favourable selectivity indexes. These findings, besides validating cell-surface-expressed NCL as an antiviral target, open the way for the possible use of AS1411 as a new potent and promisingly safe anti-HIV-1 agent.

1 July 2021 in Frontiers in Cellular and Infection Microbiology
Verified
Journal Article
Open access
JBJennifer P. Bharucha
Jennifer P. Bharucha
LSLingling Sun
Lingling Sun
WLWuyuan Lu
Wuyuan Lu
SGSuzanne Gartner
Suzanne Gartner
AGAlfredo Garzino-Demo
Alfredo Garzino-Demo
Human beta-defensins (hBDs) are broad-spectrum antimicrobial peptides, secreted by epithelial cells of the skin and mucosae, and astrocytes, which we and others have shown to inhibit HIV-1 in primary CD4+T cells. Although loss of CD4+T cells contributes to mucosal immune dysfunction, macrophages are a major source of persistence and spread of HIV and also contribute to the development of various HIV-associated complications. We hypothesized that, besides T cells, hBDs could protect macrophages from HIV. Our data in primary human monocyte-derived macrophages (MDM)in vitroshow that hBD2 and hBD3 inhibit HIV replication in a dose-dependent manner. We determined that hBD2 neither alters surface expression of HIV receptors nor induces expression of anti-HIV cytokines or beta-chemokines in MDM. Studies using a G-protein signaling antagonist in a single-cycle reporter virus system showed that hBD2 suppresses HIV at an early post-entry stageviaG-protein coupled receptor (GPCR)-mediated signaling. We find that MDM express the shared chemokine-hBD receptors CCR2 and CCR6, albeit at variable levels among donors. However, cell surface expression analyses show that neither of these receptors is necessary for hBD2-mediated HIV inhibition, suggesting that hBD2 can signalviaadditional receptor(s). Our data also illustrate that hBD2 treatment was associated with increased expression of APOBEC3A and 3G antiretroviral restriction factors in MDM. These findings suggest that hBD2 inhibits HIV in MDMviamore than one CCR thus adding to the potential of using β-defensins in preventive and therapeutic approaches.

28 August 2013 in Retrovirology
Verified
Journal Article
Open access
PDF file
SCSabrina Curreli
Sabrina Curreli
SKSelvi Krishnan
Selvi Krishnan
MRMarvin Reitz
Marvin Reitz
YLYanto Lunardi-Iskandar
Yanto Lunardi-Iskandar
MLMark K Lafferty
Mark K Lafferty
JBJoseph Bryant
Joseph Bryant
Human Immunodeficiency Virus Type I (HIV-1) infection is associated with a high incidence of B-cell lymphomas. The role of HIV in these lymphomas is unclear and currently there are no valid in vivo models for better understanding HIV-related lymphomagenesis. Transgenic (Tg) 26 mice have a 7.4-kb pNL4-3 HIV-1 provirus lacking a 3.1-kb sequence encompassing parts of the gag-pol region. Approximately 15% of these HIV Tg mice spontaneously develop lymphoma with hallmark pre-diagnostic markers including skin lesions, diffuse lymphadenopathy and an increase in pro-inflammatory serum cytokines. Here we describe the phenotypic and molecular characteristics of the B cell leukemia/lymphoma in the Tg mice.

31 October 2016 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
VCVirginia A. Carroll
Virginia A. Carroll
MLMark K. Lafferty
Mark K. Lafferty
LMLuigi Marchionni
Luigi Marchionni
JBJoseph L. Bryant
Joseph L. Bryant
RGRobert Gallo
Robert Gallo
AGAlfredo Garzino-Demo
Alfredo Garzino-Demo
Significance: Non-Hodgkin lymphomas are associated with HIV infection. Current hypotheses on lymphomagenesis, based on immunosuppression and/or activation and/or inflammation, are generic and do not provide mechanistic, testable models. Here we show that several HIV proteins are expressed in a HIV transgenic mouse model of lymphoma, but only Matrix/p17 is consistently expressed at high levels even in early disease stages. Microarray analyses of gene expression showed an enrichment of recombination-activating genes (Rag1/2) in mouse lymphoma tissue. When activated human B cells were treated with p17, induction of RAG1 expression was observed in three of seven donors. Taken together, and in the context of the literature, our results point to the involvement of p17 in supporting B-cell growth and genetic instability.

16 May 2017 in Viruses
Verified
Journal Article
Open access
PDF file
MLMark Lafferty
Mark Lafferty
LSLingling Sun
Lingling Sun
ACAaron Christensen-Quick
Aaron Christensen-Quick
WLWuyuan Lu
Wuyuan Lu
AGAlfredo Garzino-Demo
Alfredo Garzino-Demo
Chemokine receptor type 6 (CCR6)+CD4+ T cells are preferentially infected and depleted during HIV disease progression, but are preserved in non-progressors. CCR6 is expressed on a heterogeneous population of memory CD4+ T cells that are critical to mucosal immunity. Preferential infection of these cells is associated, in part, with high surface expression of CCR5, CXCR4, and α4β7. In addition, CCR6+CD4+ T cells harbor elevated levels of integrated viral DNA and high levels of proliferation markers. We have previously shown that the CCR6 ligands MIP-3α and human beta defensins inhibit HIV replication. The inhibition required CCR6 and the induction of APOBEC3G. Here, we further characterize the induction of apolipoprotein B mRNA editing enzyme (APOBEC3G) by human beta defensin 2. Human beta defensin 2 rapidly induces transcriptional induction of APOBEC3G that involves extracellular signal-regulated kinases 1/2 (ERK1/2) activation and the transcription factors NFATc2, NFATc1, and IRF4. We demonstrate that human beta defensin 2 selectively protects primary CCR6+CD4+ T cells infected with HIV-1. The selective protection of CCR6+CD4+ T cell subsets may be critical in maintaining mucosal immune function and preventing disease progression.